ADMS — Adamas Pharmaceuticals Share Price
Last Trade - 00:00- $195.94m
- $200.84m
- $79.29m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.57 | 0.57 | 34.05 | 54.64 | 74.46 | 94.8 | 124.81 | 107.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
Directors
- David Mahoney CHM (66)
- Neil McFarlane (47)
- Christopher Prentiss CFO (45)
- Adrian Quartel
- Vijay Shreedhar (49)
- Michael Bigham (62)
- Martha Demski (68)
- William Ericson (62)
- John MacPhee IND (45)
- Spyridon Papapetropoulos (48)
- Anna Richo (60)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- November 15th, 2000
- Public Since
- April 10th, 2014
- No. of Shareholders
- 17
- No. of Employees
- 138
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 45,408,095
- Address
- 1900 Powell St Ste 1000, EMERYVILLE, 94608-1839
- Web
- https://adamaspharma.com/
- Phone
- +1 5104503554
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ADMS
Upcoming events for ADMS
Q3 2021 Adamas Pharmaceuticals Inc Earnings Release
Similar to ADMS
AC IMMUNE SA ORD
NASDAQ Global Market
ADICET BIO ORD
NASDAQ Global Market
AEROVATE THERAPEUTICS ORD
NASDAQ Global Market
AMICUS THERAPEUTICS ORD
NASDAQ Global Market
ARCTURUS THERAPEUTICS HOLDINGS ORD
NASDAQ Global Market
FAQ
As of Today at 19:55 UTC, shares in Adamas Pharmaceuticals are trading at $4.32. This share price information is delayed by 15 minutes.
Shares in Adamas Pharmaceuticals last closed at $4.32 and the price had moved by -14.55% over the past 365 days. In terms of relative price strength the Adamas Pharmaceuticals share price has underperformed the S&P500 Index by -35.17% over the past year.
The overall consensus recommendation for Adamas Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Adamas Pharmaceuticals does not currently pay a dividend.
Adamas Pharmaceuticals does not currently pay a dividend.
Adamas Pharmaceuticals does not currently pay a dividend.
To buy shares in Adamas Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.32, shares in Adamas Pharmaceuticals had a market capitalisation of $195.94m.
Here are the trading details for Adamas Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ADMS
Based on an overall assessment of its quality, value and momentum Adamas Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adamas Pharmaceuticals is $8.79. That is 103.71% above the last closing price of $4.32.
Analysts covering Adamas Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adamas Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -34.5%.
As of the last closing price of $4.32, shares in Adamas Pharmaceuticals were trading -13.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adamas Pharmaceuticals.
Adamas Pharmaceuticals' management team is headed by:
- David Mahoney - CHM
- Neil McFarlane -
- Christopher Prentiss - CFO
- Adrian Quartel -
- Vijay Shreedhar -
- Michael Bigham -
- Martha Demski -
- William Ericson -
- John MacPhee - IND
- Spyridon Papapetropoulos -
- Anna Richo -
We do not have data on Adamas Pharmaceuticals' shareholders